Abstract:What is this summary about?This is a plain language summary of an article that describes the first results of the phase 3 PAPILLON study in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with Exon 20 insertion (Ex20ins) mutations in the epidermal growth factor receptor (EGFR) gene who had not had any cancer treatment before. Researchers looked at how safe and effective the bispecific antibody amivantamab (brand name: RYBREVANT (R)) plus chemotherapy was in comparison to chemotherapy alone.Amivantamab was approved by the US Food and Drug Administration (FDA) in May 2021 for patients with the same type of cancer who got worse after chemotherapy. In March 2024, amivantamab was approved in combination with chemotherapy for previously untreated patients with the same type of cancer. The National Comprehensive Cancer Network (R) (NCCN (R)) recommends amivantamab plus chemotherapy as a preferred first treatment option for these patients. What is this summary about?This is a plain language summary of an article that describes the first results of the phase 3 PAPILLON study in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with Exon 20 insertion (Ex20ins) mutations in the epidermal growth factor receptor (EGFR) gene who had not had any cancer treatment before. Researchers looked at how safe and effective the bispecific antibody amivantamab (brand name: RYBREVANT (R)) plus chemotherapy was in comparison to chemotherapy alone.Amivantamab was approved by the US Food and Drug Administration (FDA) in May 2021 for patients with the same type of cancer who got worse after chemotherapy. In March 2024, amivantamab was approved in combination with chemotherapy for previously untreated patients with the same type of cancer. The National Comprehensive Cancer Network (R) (NCCN (R)) recommends amivantamab plus chemotherapy as a preferred first treatment option for these patients. What were the results?308 patients were randomly selected to receive amivantamab plus chemotherapy or chemotherapy alone. Patients who received amivantamab plus chemotherapy lived longer without having their disease get worse compared to those who had chemotherapy. Patients who had amivantamab plus chemotherapy also had the risk of their disease getting worse or dying reduced by 60% compared to chemotherapy. After 18 months of treatment, 31% of patients on amivantamab plus chemotherapy did not have their cancer grow or spread compared to 3% with chemotherapy. More than 7 in 10 patients who had amivantamab plus chemotherapy had tumors that shrank by at least 30% or were no longer detectable. This only happened in less than 5 in 10 patients who had chemotherapy alone.All patients had side effects, with the most common being neutropenia (occurring in 59% of patients), paronychia (56%), and rash/red skin bumps (54%/31%) for those treated with amivantamab plus chemotherapy, and anemia (55%), neutropenia (45%), and nausea (42%) for those treated with chemotherapy. Few patients (7%) stopped taking amivantamab due to side effects. What were the results?308 patients were randomly selected to receive amivantamab plus chemotherapy or chemotherapy alone. Patients who received amivantamab plus chemotherapy lived longer without having their disease get worse compared to those who had chemotherapy. Patients who had amivantamab plus chemotherapy also had the risk of their disease getting worse or dying reduced by 60% compared to chemotherapy. After 18 months of treatment, 31% of patients on amivantamab plus chemotherapy did not have their cancer grow or spread compared to 3% with chemotherapy. More than 7 in 10 patients who had amivantamab plus chemotherapy had tumors that shrank by at least 30% or were no longer detectable. This only happened in less than 5 in 10 patients who had chemotherapy alone.All patients had side effects, with the most common being neutropenia (occurring in 59% of patients), paronychia (56%), and rash/red skin bumps (54%/31%) for those treated with amivantamab plus chemotherapy, and anemia (55%), neutropenia (45%), and nausea (42%) for those treated with chemotherapy. Few patients (7%) stopped taking amivantamab due to side effects. What do the results mean?Amivantamab plus chemotherapy worked well to extend the time that patients' cancer did not worsen. Patients had a 60% lower risk of death or having their cancer worsen compared to those who had chemotherapy. These benefits were seen in groups of patients with different characteristics.Amivantamab plus chemotherapy works well, is well tolerated, and is a good treatment option for untreated patients who have advanced NSCLC with EGFR Ex20ins mutations. What do the results mean?Amivantamab plus chemotherapy worked well to extend the time that patients' cancer did not worsen. Patients had a 60% lower risk of death or having their cancer worsen compared to those who had chemotherapy. These benefits were seen in groups of patients with different characteristics.Amivantamab plus chemotherapy works well, is well tolerated, and is a good treatment option for untreated patients who have advanced NSCLC with EGFR Ex20ins mutations.

513MO Amivantamab Plus Chemotherapy Vs Chemotherapy As a First-Line Treatment among Asian Patients with EGFR Exon 20 Insertion-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): PAPILLON Subgroup Analysis

Amivantamab Plus Chemotherapy Vs Chemotherapy As First-Line Treatment among Patients with EGFR Exon 20 Insertion–mutated Advanced Non-Small Cell Lung Cancer (NSCLC): PAPILLON Chinese Subgroup Analysis.

Plain Language Summary of PAPILLON: Amivantamab Plus Chemotherapy in Untreated EGFR -Mutated Non-Small-cell Lung Cancer

Abstract CT054: Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study

445P Overall Survival (OS) with Afatinib (A) Vs Chemotherapy (CT) in Patients (pts) with NSCLC Harboring EGFR Mutations (mut): Subgroup Analyses by Race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

LBA10 Amivantamab Plus Lazertinib Vs Osimertinib As First-Line Treatment among Asian Patients with EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis

Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.

Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.

Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.

Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC: Results from the Phase IV MO19390 (sail) Study

Final Safety and Efficacy Data for Asian Patients (pts) in the MO19390 (sail) Trial: First-line Bevacizumab (bv) Plus Chemotherapy in Advanced or Recurrent Non-Small Cell Lung Cancer (NSCLC).

Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.

OA11 First-Line Nivolumab + Ipilimumab in Asian Patients with Advanced NSCLC and High TMB (≥10 Mut/mb): Results from CheckMate 227

Phase 3 Study of First-Line Crizotinib Vs Pemetrexed−cisplatin/carboplatin (PCC) in East Asian Patients (pts) with ALK+ Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

1192MO Amivantamab Monotherapy and in Combination with Lazertinib in Post-Osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS Study

Amivantamab Plus Lazertinib in Atypical EGFR-mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Results from CHRYSALIS-2.

A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Amivantamab Plus Lazertinib Vs Osimertinib in First-Line EGFR-mutant Advanced Non-Small Cell Lung Cancer (NSCLC) with Biomarkers of High-Risk Disease: A Secondary Analysis from the Phase 3 MARIPOSA Study.